期刊文献+

哺乳妇女单次注射迪波盖司通~长效避孕针后血清和乳液中MPA浓度变化 被引量:1

Concentration Changes of Medroxyprogesterone Acetate in Serum and Milk in Lactating Woman Who Used Depo Geston~
下载PDF
导出
摘要 目的:探讨中国妇女哺乳期使用迪波盖司通后血清和乳液醋酸甲羟孕酮(MPA)浓度变化。方法:10名产后哺乳妇女单次注射迪波盖司通(含MPA150mg),在注射后的第1、2、4、6、8、10和12周采集血样和乳液样本,用放射免疫方法测定MPA。结果:血清MPA浓度于注射后第1周最高,到第2、4周时下降明显,第4周后浓度下降趋势逐渐缓慢。乳液MPA浓度在第1周为最高,第2周比第1周降低了约1/2,之后10周平均浓度变化波动在5.09-8.15ng/ml之间。观察期间乳液/血清MPA浓度比值和曲线下浓度面积比值均为0.55。对象之间和同一对象不同时间点乳液/血清MPA浓度存在明显个体差异。结论:哺乳期使用迪波盖司通,将导致血液和乳液中含有一定量的MPA。 Objective: To determine the concentration changes of medroxyprogesterone acetate (MPA) in serum and milk in the Chinese lactating women who used Depo Geston. Methods: Ten postpartum and breastfeeding women received an injectable contraceptive of Depo Geston (depo medroxyprogesterone acetate, DMPA, 150 mg/ampoule). Serum and milk samples were collected in the 1st, 2nd, 4th, 6th, 8th 10th and 12th week after contraceptive injection. The concentrations of medroxyprogesterone acetate (MPA) in serum and milk were determined by radioimmunoassay. Results: The highest MPA concentration in serum was observed at the 1st week and then the level of serum MPA decreased obviously at the 2nd and 4th week. After the 4th week, the decline of serum MPA level slowed down. The concentration of milk MPA reached the highest level at 1st week. But at the 2nd week the average level of MPA in milk dropped by half. The MPA concentration in the milk was changed in the range of 5.2-8.3 ng/ml in the following 10 weeks. During observation, the average ratios of concentration and area under curve (AUC) in milk/serum were both 0.55. There was a wide variation in MPA concentrations and ratios of milk/serum between subjects. Conclusion: MPA concentrations maintained a certaim level at the 12th week after DMPA injection. However, whether mather's intake of DMPA during feeding period has effect on children's growth, espcially pubertal growth, deserves further studies.
出处 《生殖与避孕》 CAS CSCD 北大核心 2005年第8期474-477,490,共5页 Reproduction and Contraception
关键词 醋酸甲羟孕酮避孕针 哺乳期 血清/乳液MPA浓度比值 depot medroxyprogesterone acetate (DMPA) injectable contraceptive duration of lactation MPA concentration and ratio in serum/milk
  • 相关文献

参考文献11

  • 1Sun DL, Shao QX & Sang GW. A multicentered clinical trial of the long-acting injectable contraceptive Depo Provera in Chinese women. Contraception, 2000, 62(1): 15-8. 被引量:1
  • 2邵庆翔,蒋海瑛,付伟,范涯,桑国卫.长效避孕针醋酸甲羟孕酮引入性试验[J].中华妇产科杂志,1999,34(1):36-39. 被引量:3
  • 3Saxena BN, Shrimanker K & Grudzinskas JG. Levels of contraceptive steroids in breast milk and plasma of lactating women. Contraception, 1977, 16(6):605-13. 被引量:1
  • 4Tieng P, Chalong Y & Ronald. The long-term growth and development of children exposed to Depo-provera during pregnancy or lactation. Contraception, 1992, 45(4):313-24. 被引量:1
  • 5Koetsawang S. Injected long-acting medroxyprogesterone acetate: effect on human lactation and concentration in milk.Journal of the Medical Association of Thailand, 1977, 60(2):57-60. 被引量:1
  • 6Koetsawang S, Nukularn P & Fotherby K. Transfer of contraceptive steroids in milk of women using long-acting gestagens. Contraception, 1982, 25(4):321-31. 被引量:1
  • 7ToaffR, Ashkenazi H, Schwartz A, et al. Effects ofoestrogen and progestagen on the composition of human milk. J Reprod Fertil, 1969, 19:475-82. 被引量:1
  • 8Emery M. Can a woman breastfeed while using Depoprovera as a agent for birth control? J Hum Lact, 1993, 9(3):187-8. 被引量:1
  • 9Sas M., Gellen JJ, Dusitsin N, et al. An investigation on the influence of steroidal contraceptives on milk lipid and fatty acids in Hungary and Thailand. Contraception, 1986, 33(2):159-78. 被引量:1
  • 10WHO Task Force for Epidemiological Research on Reproductive Health, Special Programme of Research, Development and Research Training in Human Reproduction.Progestogen-only contraceptives during lactating: I. Infant growth. Contraception, 1994, 50(1): 35-68. 被引量:1

二级参考文献5

共引文献3

同被引文献7

  • 1曹爽,薛晓鸥.子宫肌瘤细胞培养方法之比较[J].锦州医学院学报,2004,25(3):16-18. 被引量:3
  • 2黄杰雄.增殖细胞核抗原的研究进展[J].国外医学(生理病理科学与临床分册),1994,14(1):9-11. 被引量:94
  • 3Venkatachalam S, Bagratee J S, Moodey J. Medical management of uterine fibroids with medroxyprogesterone acetate (Depo provera): a pilot study [J]. Obstet Gynaecol,2004, 24(7): 798-800. 被引量:1
  • 4Grigoriev V, Chen-Mok M, Tarasova M, et al. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas [ J ]. Fertil Steril, 2003, 79 (5) : 1194 - 1198. 被引量:1
  • 5Luukkainen T, Lhteemki P, Toivonen J. Levonorgestrel-releasing intrauterine device [J]. Ann Med, 1990,22 (2) : 85-90. 被引量:1
  • 6Xiao B L, Zhu P D, Wu S C, et al. Effect of levonorgestrel- releasing intrauterine device on hormonal profile and menstrual pattern after long-term use [ J ]. Contraception, 1995,51 (6) : 359- 365. 被引量:1
  • 7Yamada T, Nakago S, Kurachi O, et al. Progesterone downregulates insulin-like growth factor- I expression in cultured human uterine leiomyoma cells [ J ]. Human Reproduction, 2004,19 (4) : 815-821. 被引量:1

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部